Attached files

file filename
EX-23.1 - CONSENT OF ERNST & YOUNG LLP - AVEO PHARMACEUTICALS, INC.d264862dex231.htm
EX-32.2 - CERTIFICATION OF PFO PURSUANT TO SECTION 906 - AVEO PHARMACEUTICALS, INC.d264862dex322.htm
EX-21.1 - SUBSIDIARIES - AVEO PHARMACEUTICALS, INC.d264862dex211.htm
EX-32.1 - CERTIFICATION OF PEO PURSUANT TO SECTION 906 - AVEO PHARMACEUTICALS, INC.d264862dex321.htm
EX-31.2 - CERTIFICATION OF PFO PURSUANT TO SECTION 302 - AVEO PHARMACEUTICALS, INC.d264862dex312.htm
EX-31.1 - CERTIFICATION OF PEO PURSUANT TO SECTION 302 - AVEO PHARMACEUTICALS, INC.d264862dex311.htm
EX-10.8 - FORM OF RESTRICTED STOCK AGREEMENT - AVEO PHARMACEUTICALS, INC.d264862dex108.htm
EX-10.25 - AMENDMENT NO. 1 TO LOAN & SECURITY AGREEMENT - AVEO PHARMACEUTICALS, INC.d264862dex1025.htm
EX-10.29 - FIRST AMENDMENT TO SUBLEASE - AVEO PHARMACEUTICALS, INC.d264862dex1029.htm
EXCEL - IDEA: XBRL DOCUMENT - AVEO PHARMACEUTICALS, INC.Financial_Report.xls
10-K - FORM 10-K - AVEO PHARMACEUTICALS, INC.d264862d10k.htm

Exhibit 10.23

 

LOGO   

AVEO Pharmaceuticals, Inc.

75 Sidney Street

Cambridge, MA 02139

 

www.aveopharma.com

October 31, 2011

Raju Kucherlapati, PhD

6 Wildflower Lane

Weston, MA 02493

Re: Consulting and Scientific Advisory Board Agreement by and between Raju Kucherlapati, PhD and AVEO Pharmaceuticals, Inc. effective as of January 1, 2010 (the “Agreement”)

Dear Dr. Kucherlapati,

It is hereby agreed that Section 2 of the Agreement shall be amended to extend the Consultation Period through and including December 31, 2013 unless sooner terminated in accordance with Section 11 of the Agreement. All other terms and obligations under the Agreement shall remain the same.

 

Sincerely,

/s/ Murray O. Robinson

Murray O. Robinson, PhD
Senior Vice President, Translational Research
Chair of the Scientific Advisory Board

 

Agreed and Acknowledged:            

/s/ Raju Kucherlapati

   

November 3, 2011

 
Raju Kucherlapati, PhD     Date